Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 9/20 | 0.39 |
| ▸ | JAK2 | O60674 | 2/20 | 0.37 |
| ▸ | JAK1 | P23458 | 2/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | MMP1 | P03956 | 1/20 | 0.35 |
| ▸ | MMP9 | P14780 | 1/20 | 0.35 |
| ▸ | MMP13 | P45452 | 1/20 | 0.35 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.35 |
| ▸ | AXL | P30530 | 1/20 | 0.35 |
| ▸ | MERTK | Q12866 | 1/20 | 0.35 |
| ▸ | BRS3 | P32247 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3479399 | 0.92 | BACE1 (0.41) | BACE1FAAHMMP1MMP9MMP13 | |
| SCHEMBL3479457 | 0.90 | BACE1 (0.39) | BACE1JAK2JAK1NR1H2FAAH | |
| SCHEMBL3479554 | 0.88 | JAK2 (0.37) | BACE1JAK2JAK1NR1H2MMP1 | |
| Trifluoroacetic Acid SCHEMBL3479514 | 0.87 | BACE1 (0.38) | BACE1FAAHMMP1MMP9MMP13 | |
| SCHEMBL13031015 | 0.87 | JAK2 (0.36) | BACE1JAK2JAK1NR1H2MMP1 | |
| SCHEMBL3479696 | 0.86 | BACE1 (0.37) | BACE1JAK2JAK1NR1H2MMP1 | |
| Trifluoroacetic Acid SCHEMBL3479655 | 0.86 | BACE1 (0.36) | BACE1JAK2JAK1NR1H2FAAH | |
| SCHEMBL3479470 | 0.86 | JAK2 (0.35) | BACE1JAK2JAK1NR1H2MMP1 | |
| Trifluoroacetic Acid SCHEMBL3479427 | 0.84 | NR1H2 (0.35) | BACE1JAK2JAK1NR1H2FAAH | |
| SCHEMBL592547 | 0.84 | JAK2 (0.36) | JAK2JAK1NR1H2MMP1MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298342-A1 | Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's Disease | MERCK & CO., INC. (US) | 2010-11-25 | — | — | US | claimed |
| US-20100298342-A1 | Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's Disease | MERCK & CO., INC. (US) | 2010-11-25 | — | — | US | disclosed |
| US-20100298342-A1 | Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's Disease | MERCK & CO., INC. (US) | 2010-11-25 | — | — | US | disclosed |
| US-20100298342-A1 | Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's Disease | MERCK & CO., INC. (US) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298342-A1 | Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's Disease | BACE1, APP, PSEN1 | BACE1 1/4885JAK2 4818/4885JAK1 4835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.